Biohaven Pharmaceutical Holding Company (NYSE: BHVN) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “The prescription ramp for Nurtec ODT in acute migraine continues to beat our expectations, with weekly Symphony prescription volumes ahead of our forecasts. With 3Q20 coming to a close, we are updating our BHVN model to incorporate additional reported weekly Symphony data but also increasing our gross-to-net (‘GTN’) as we believe GTN will likely be under pressure in the near term but should improve over time. As a result, we are lowering our 3Q20 sales forecast from $20M to $18M (vs ~$19M consensus) driven by the higher GTN. We maintain our Buy rating and $82 PT.”
To request access to the full report, visit http://nnw.fm/SaZ9d
About Biohaven Pharmaceutical Holding Company Ltd.
Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has combined internal development and research with intellectual property licensed from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, Rutgers and ALS Biopharma LLC and. Our progress is fueled by an entrepreneurial organizational structure and an impressive range of experience in drug development along with the confident support of top-tier biopharma investors. Currently, Biohaven’s lead development programs include multiple compounds across its CGRP receptor antagonist and glutamate modulator platforms. Biohaven’s common shares are listed on the New York Stock Exchange and traded under the ticker symbol BHVN. For more information, visit the company’s website at www.BiohavenPharma.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
